Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;10(Suppl 9):S1108-S1112.
doi: 10.21037/jtd.2018.03.180.

Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study

Takehiro Uemura  1 , Toyoaki Hida  1
Affiliations
Editorial

Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study

Takehiro Uemura et al. J Thorac Dis. 2018 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: T Hida has received grants and personal fees from AstraZeneca, Ono Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly; Novartis; Taiho Pharmaceutical Co., Ltd.; Nippon Boehringer Ingelheim; Pfizer; Bristol-Meyers Squibb; Clovis Oncology; MSD; and Kissei and grants from Eisai; Takeda Pharmaceutical Co., Ltd.; Dainippon Sumitomo Pharma; Abbvie; Merck Serono; Kyowa Hakko Kirin; Daiichi Sankyo; Astellas; Ignyta; and Servier. T Uemura has no conflicts of interest to declare.

Comment on

  • Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Clinical Trial.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. 10.3322/caac.21442 - DOI - PubMed
    1. Ahn JS, Ahn YC, Kim JH, et al. Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol 2015;33:2660-6. 10.1200/JCO.2014.60.0130 - DOI - PubMed
    1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90. 10.1200/JCO.2009.26.2543 - DOI - PubMed
    1. NSCLC Meta-analyses Collaborative Group , Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375:1267-77. 10.1016/S0140-6736(10)60059-1 - DOI - PMC - PubMed
    1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909. 10.1136/bmj.311.7010.899 - DOI - PMC - PubMed

LinkOut - more resources